Jakub Svoboda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jakub Svoboda has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Lauren Strelec
University of Pennsylvania, Philadelphia, PA, USA
3 shared publicationsStephen J. Schuster
University of Pennsylvania, Philadelphia, PA, USA
3 shared publicationsDaniel J. Landsburg
University of Pennsylvania, Philadelphia, PA, USA
2 shared publicationsSarah J. Nagle
Oregon Health and Science University, Portland, OR, USA
2 shared publications- Steven Michael Bair
University of Colorado School of Medicine, Aurora, Colorado, United States
2 shared publications Sunita Dwivedy Nasta
University of Pennsylvania, Philadelphia, PA, USA
2 shared publications
Latest Publications
- Open Access
- 15 May 2020
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 106 (6) , 1705-1713
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas
We conducted a phase I/II multicenter trial using 6 cycles of brentuximab vedotin (BV) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for treatment of patients with CD30-positive (+) B-cell lymphomas. Thirty-one patients were evaluable for toxicity and 29 for efficacy including 22 with primary mediastinal B-cell lymphoma (PMBCL), 5 with diffuse large B-cell lymphoma (DLBCL), and 2 with gray zone lymphoma (GZL). There were no treatment-related deaths; 32% of patients had non-hematological grade 3/4 toxicities. The overall response rate was 100% (95% CI: 88-100) with 86% (95% CI: 68-96) of patients achieving complete response at the end of systemic treatment. Consolidative radiation following end of treatment response assessment was permissible and used in 52% of all patients including 59% of patients with PMBCL. With a median follow-up of 30 months, the 2-year progression-free survival (PFS) and overall survival (OS) were 85% (95% CI: 66-94) and 100%, respectively. In the PMBCL cohort, 2-year PFS was 86% (95% CI: 62-95). In summary, BV-R-CHP with or without consolidative radiation is a feasible and active frontline regimen for CD30+ B-cell lymphomas (NCT01994850).
- 15 May 2020
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 106 (6) , 1705-1713
Open AccessBrentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas
We conducted a phase I/II multicenter trial using 6 cycles of brentuximab vedotin (BV) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for treatment of patients with CD30-positive (+) B-cell lymphomas. Thirty-one patients were evaluable for toxicity and 29 for efficacy including 22 with primary mediastinal B-cell lymphoma (PMBCL), 5 with diffuse large B-cell lymphoma (DLBCL), and 2 with gray zone lymphoma (GZL). There were no treatment-related deaths; 32% of patients had non-hematological grade 3/4 toxicities. The overall response rate was 100% (95% CI: 88-100) with 86% (95% CI: 68-96) of patients achieving complete response at the end of systemic treatment. Consolidative radiation following end of treatment response assessment was permissible and used in 52% of all patients including 59% of patients with PMBCL. With a median follow-up of 30 months, the 2-year progression-free survival (PFS) and overall survival (OS) were 85% (95% CI: 66-94) and 100%, respectively. In the PMBCL cohort, 2-year PFS was 86% (95% CI: 62-95). In summary, BV-R-CHP with or without consolidative radiation is a feasible and active frontline regimen for CD30+ B-cell lymphomas (NCT01994850).
- 1 February 2019
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 19 (2) , 109-115
Bexarotene in Patients With Peripheral T-cell Lymphomas: Results of a Retrospective Study
- 1 February 2019
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 19 (2) , 109-115
Bexarotene in Patients With Peripheral T-cell Lymphomas: Results of a Retrospective Study
- 1 June 2018
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 18 (6) , 380-391
Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm
- 1 June 2018
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 18 (6) , 380-391
Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm
- 9 June 2017
- Published by Wiley in American Journal of Hematology
- Vol. 92 (9) , 879-884
Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis
Patients with relapsed/refractory Hodgkin lymphoma (RR‐HL) who progress or relapse following autologous stem cell transplantation (ASCT) have historically had a poor prognosis. Several novel agents, particularly brentuximab vedotin, have shown efficacy in this setting. However, there remains a paucity of data characterizing outcomes outside of clinical trials and how these novel agents have impacted prognosis in general population of patients with RR‐HL. Here, we conducted a retrospective analysis to evaluate outcomes in 87 patients with RR‐HL with relapse post‐ASCT. Treatment with novel agents (including brentuximab vedotin) was associated with significant improvement in median overall survival (OS) compared to patients who did not receive novel agents (85.6 vs 17.1 months;P < .001). Additional factors associated with improved OS in univariate analysis include treatment with radiation therapy post‐ASCT (34.1 vs 17.0 months;P = .015), chemosensitivity (i.e., relapsed compared to primary refractory disease; 51.8 vs 25.6 months; p = 0.013), initial response to ASCT (i.e., CR/PR compared to SD/PD; 46.1 vs 20.4 months;P = .011), and transplantation in 2010 and later compared to prior to 2010 (not reached vs 24.5 months;P = .025). The current study demonstrates markedly improved OS in RR‐HL patients treated with novel therapeutics and lends “real world” credence to the role of these agents in improving outcomes in the current era.
- 9 June 2017
- Published by Wiley in American Journal of Hematology
- Vol. 92 (9) , 879-884
Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis
Patients with relapsed/refractory Hodgkin lymphoma (RR‐HL) who progress or relapse following autologous stem cell transplantation (ASCT) have historically had a poor prognosis. Several novel agents, particularly brentuximab vedotin, have shown efficacy in this setting. However, there remains a paucity of data characterizing outcomes outside of clinical trials and how these novel agents have impacted prognosis in general population of patients with RR‐HL. Here, we conducted a retrospective analysis to evaluate outcomes in 87 patients with RR‐HL with relapse post‐ASCT. Treatment with novel agents (including brentuximab vedotin) was associated with significant improvement in median overall survival (OS) compared to patients who did not receive novel agents (85.6 vs 17.1 months;P < .001). Additional factors associated with improved OS in univariate analysis include treatment with radiation therapy post‐ASCT (34.1 vs 17.0 months;P = .015), chemosensitivity (i.e., relapsed compared to primary refractory disease; 51.8 vs 25.6 months; p = 0.013), initial response to ASCT (i.e., CR/PR compared to SD/PD; 46.1 vs 20.4 months;P = .011), and transplantation in 2010 and later compared to prior to 2010 (not reached vs 24.5 months;P = .025). The current study demonstrates markedly improved OS in RR‐HL patients treated with novel therapeutics and lends “real world” credence to the role of these agents in improving outcomes in the current era.
- 27 October 2012
- Published by Springer Nature
- p. 67-80
Clinical Implications of Burkitt Lymphoma
- Open Access
- 12 June 2006
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 38 (3) , 211-216
Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation
We conducted a retrospective analysis of 50 lymphoma patients (Hodgkin's disease and non-Hodgkin's lymphoma) who had an 18F-fluoro-deoxyglucose positron emission tomography (FDG-PET) scan after at least two cycles of salvage chemotherapy and before autologous stem cell transplantation (ASCT) at our institution. The patients were categorized into FDG-PET negative (N=32) and positive (N=18) groups. The median follow-up after ASCT was 19 months (range: 3–59). In the FDG-PET-negative group, the median progression-free survival (PFS) was 19 months (range: 2–59) with 15 (54%) patients without progression at 12 months after ASCT. The median overall survival (OS) for this group was not reached. In the FDG-PET-positive group, the median PFS was 5 months (range: 1–19) with only one (7%) patient without progression at 12 months after ASCT. The median OS was 19 months (range: 1–34). In the FDG-PET-negative group, chemotherapy-resistant patients by CT-based criteria had a comparable outcome to those with chemotherapy-sensitive disease. A positive FDG-PET scan after salvage chemotherapy and prior ASCT indicates an extremely poor chance of durable response after ASCT.
- 12 June 2006
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 38 (3) , 211-216
Open AccessPrognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation
We conducted a retrospective analysis of 50 lymphoma patients (Hodgkin's disease and non-Hodgkin's lymphoma) who had an 18F-fluoro-deoxyglucose positron emission tomography (FDG-PET) scan after at least two cycles of salvage chemotherapy and before autologous stem cell transplantation (ASCT) at our institution. The patients were categorized into FDG-PET negative (N=32) and positive (N=18) groups. The median follow-up after ASCT was 19 months (range: 3–59). In the FDG-PET-negative group, the median progression-free survival (PFS) was 19 months (range: 2–59) with 15 (54%) patients without progression at 12 months after ASCT. The median overall survival (OS) for this group was not reached. In the FDG-PET-positive group, the median PFS was 5 months (range: 1–19) with only one (7%) patient without progression at 12 months after ASCT. The median OS was 19 months (range: 1–34). In the FDG-PET-negative group, chemotherapy-resistant patients by CT-based criteria had a comparable outcome to those with chemotherapy-sensitive disease. A positive FDG-PET scan after salvage chemotherapy and prior ASCT indicates an extremely poor chance of durable response after ASCT.